Production address: No. 2, Zhongyu South Road, Xixiangtang District, Nanning City
China's traditional Chinese medicine (TCM) industry has topped 7 billion yuan
In recent years, the state has encouraged the development of traditional Chinese medicine, but at the same time, the supervision of traditional Chinese medicine injections has become more and more strict, and the development of new Chinese patent medicine is difficult.
At present, on the Chinese market, kangmei pharmaceutical, China traditional Chinese medicine, hongri pharmaceutical, xiangxue pharmaceutical and tailong pharmaceutical are listed pharmaceutical enterprises with large sales scale of TCM yinpian or TCM formula granules. Kangmei pharmaceutical co., LTD. Is the leader of traditional Chinese medicine yinpian. Recently, due to the problem of "financial fraud", it has attracted much attention, and also aroused the market's doubts on the business of traditional Chinese medicine yinpian. Chinese traditional medicine (TCM) is the leading enterprise in the TCM granule market. According to 2018 annual report data, the revenue of this business sector has significantly increased, exceeding 7 billion yuan.
All the time, as the leading enterprise of Chinese traditional medicine formula granules, Chinese traditional medicine has been able to perform well every year. In 2017, the company's total revenue reached 8.338 billion yuan, and the revenue of TCM decoction pieces + TCM formula particles reached 5.899 billion yuan. In 2018, the company's total revenue exceeded 10 billion yuan, an increase of 35.0% compared with last year, mainly due to the continuous and rapid development of the business of traditional Chinese medicine granule and the rapid expansion of the business of decoction pieces. Among them, the business of TCM formula granules contributed about 7.151 billion yuan, accounting for 63.5% of the total turnover, and the business of TCM decoction pieces contributed about 1.275 billion yuan, accounting for 11.3% of the total turnover.
In 2018, China's traditional Chinese medicine (TCM) industry layout was unified, with TCM slices and granules as the core. Led by jiangyin tianjiang pharmaceutical co., ltd. and guangdong pharmaceutical co., ltd. in accordance with their respective provincial plans, occupy strategic positions in the adjacent areas of authentic medicinal materials by means of mergers and acquisitions and self-built capital increase mode, and build bases for TCM decoction pieces and formula particles in 15 provinces (cities).
It is reported that in 2019, China plans to add six new GMP bases (including hubei, hunan, yunnan, chongqing, jiangxi and shaanxi) for TCM decoction pieces, with an additional capacity of 11,500 tons. Six GMP bases were extracted (including: jiangxi, shaanxi, yunnan, jilin, hubei and guizhou), with an additional capacity of 7,900 tons. Eight GMP bases for formula granule preparation (fujian, guizhou, shaanxi, hunan, hubei, yunnan, chongqing and jiangxi) have added 4,000 tons of production capacity, basically completing the coverage of the country's core provinces and cities.
In addition, in order to realize the rapid development of TCM yinpian sector as soon as possible, on the one hand, the company USES the existing sales team and channels of TCM formula particles to rapidly and efficiently expand the terminal market. On the other hand, the brand of decoction pieces should be built comprehensively, and the classified sales strategy of high-quality Chinese herbal decoction pieces in authentic regions should be adopted to carry out precise marketing and promotion in different markets. The company strives to obtain more provincial pilot production licenses of formula granule. Besides the original two national licenses of jiangyin tianjiang and guangdong, the company has obtained production pilot licenses of sichuan, heilongjiang, yunnan, hubei and guizhou provinces respectively.
Recently, sig pharmaceutical "financial fraud" storm never ceasing, companies on April 30, May 12, May 5, and receiving the supervision function of the Shanghai stock exchange, "media inquiries letter" and "annual report information letter", but the company respectively on May 14, and 21 May delay reply announcement, the latest announcement referred to in the "recovery time no later than May 29, 2019".
The truth is not known, but the charges have been laid. On May 17, the China securities regulatory commission (CSRC) announced the progress of its investigation into kangmei pharmaceutical, which has preliminarily found that the company's financial reports from 2016 to 2018 disclosed by the company are materially false. On May 18, kangmei pharmaceutical issued a statement "guilty plea", saying that the company had 8.879 billion yuan of capital transactions with related companies, which were used by related companies to buy shares of the company. At present, the company's stock has implemented other risk warning, "kangmei pharmaceutical" into "ST kangmei".
After the data adjustment, the operating income of kangmei pharmaceutical in 2017 was 17.579 billion yuan, and the operating income of TCM decoction pieces was 3.373 billion yuan, accounting for 19.2% of the company's total revenue. This is far from the annual report data of 2017 collected in the article "annual sales of traditional Chinese medicine decoction pieces exceed 5 billion yuan! The two listed pharmaceutical companies have achieved it" published by minenet in April 2018, "operating revenue of traditional Chinese medicine decoction pieces is 6.158 billion yuan".
In 2018, the operating revenue of kangmei pharmaceutical was 19.356 billion yuan, and the operating revenue of TCM decoction pieces was 4.142 billion yuan, accounting for 21.4% of the company's total revenue. Gross margin was 30.06%, 2.91 percentage points lower than last year.
In 2018, hongri pharmaceutical achieved revenue of 4.224 billion yuan, up 25.19% year on year, among which the sales revenue of TCM formula particles reached 2.162 billion yuan, up 23.35% year on year. The total revenue of TCM formula particles accounted for more than 50% of the company's total revenue.
In recent years, according to the development trend of the industry and the development needs of capacity layout, hongri pharmaceutical has been actively promoting the expansion strategy of formula granule, constructing the production base of formula granule producing area, and expanding the capacity of formula granule. In addition, tianjin kangrentang intelligent and information production base of TCM formula particles provides a model for intelligent manufacturing of TCM formula particles industry.
At present, the company has respectively in hebei amara, hubei, chongqing xiushan, yiyang establish nutrient-laden source in gansu, henan origin production base, with the help of the local geographical advantage, industry advantage and policy advantage, hand in hand to make with characteristic of the local industry chain of traditional Chinese medicine, Chinese herbal medicine raw material base construction of real estate, gradually realize the whole process of product process control, traceability.
In addition, the company has signed a cooperation agreement with lanzhou fuci pharmaceutical co., ltd. to lay out the gansu market of traditional Chinese medicine formula particles, and has completed the industrial and commercial registration of hongri pharmaceutical resources.
In 2018, xiangxue pharmaceutical achieved operating revenue of 2.504 billion yuan, up 14.49% year on year, among which the operating revenue of traditional Chinese medicine business totaled 925 million yuan, up 13.95% year on year, accounting for 36.9% of the company's total revenue.
In recent years, the business of xiangxue pharmaceutical traditional Chinese medicine decoction pieces has been steadily increasing, reaching 925 million yuan in 2018. If the growth trend is maintained, it is expected to break the 1 billion mark in 2019.
The company said that in the future, qiao pharmaceutical co., ltd. and hubei tianji co., ltd. will steadily promote the business development of TCM decoction pieces. As the "best Chinese producers" as the goal, to the brand construction as the core, on the basis of traditional Chinese medicine yinpian business, Chinese regional development from fountainhead, diversified products to the middle scale, standardization, modernization of downstream flow network layout, to the terminal channels development and medical treatment, health, culture and other service industries, throughout the entire base, standardization, informationization, to promote "Internet + intelligence + Internet of things" of traditional Chinese medicine pattern application, building of the new situation of Chinese medicine resources sustainable development.
In 2018, tailong pharmaceutical achieved operating revenue of 1.195 billion yuan, with a year-on-year growth of 2.26%. Among them, the business of traditional Chinese medicine decoction pieces achieved revenue of 566 million yuan, accounting for 47.4% of the company's total revenue.
In the increasingly strict regulation in the industry, and increasingly competitive market in zhejiang province, Chinese medicine yinpian health policy under the external environment, such as price fixing, too dragon pharmaceutical to effective integration of internal resources, complete production line and warehouse for the new site certification work, enable the new factory inspection center, and constantly optimize the original factory production workshop, storage and other equipment, facilities, continue to improve the quality of the Chinese medicine yinpian tisanes products and service. With the new plant gradually put into use, it will further drive the growth of sales revenue and gross profit margin of Chinese herbal decoction pieces.